Insmed Incorporated (INSM)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Insmed Incorporated (“Insmed” or “the Company”) (NASDAQ: INSM). Investors who purchased Insmed securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Insmed has violated federal securities laws.
Insmed Investigation Details
On December 17, 2025, Insmed issued a press release announcing “that the Phase 2b BiRCh study of brensocatib in patients with chronic rhinosinusitis without nasal polyps (CRSsNP) did not meet its primary or secondary efficacy endpoints in either the 10 mg or 40 mg treatment arms.” In light of the trial results, Insmed decided to discontinue development of brensocatib. On this news, Insmed’s stock price fell $31.91 per share, or 16.08%, to close at $166.55 per share on December 18, 2025.
What’s Next for Insmed Investors?
If you are aware of any facts relating to this investigation or purchased Insmed securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
No Cost to Insmed Investors
We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC For Insmed Securities Investigation?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace,” said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]
Attorney advertising.
Prior results do not guarantee similar outcomes.